April 2, 2019 – Genmed, a specialist provider of vendor neutral managed services to the NHS, today announces the appointment of Nicky Carless as national sales manager with responsibility for developing existing client accounts and winning new business involving renal, pathology and I3 (imaging, infrastructure and IT). She will work closely to support Genmed’s account management team and divisional director in a broad role involving responding to tenders, monitoring sales revenue, developing forecasts and growing the business.
The constrained capital resources in the NHS together with the need to reduce revenue costs year on year has led hospitals to seek manged service providers who can generate both economic and efficiency gains. Genmed has the proven ability to deliver both and works for over 40 NHS Trusts and Health Boards managing over 220 contracts worth in excess of £510 million.
Prior to joining Genmed, Nicky Carless worked at Leica Microsystems for 10 years in a variety of roles culminating in her being sales account manager responsible for the company’s histopathology portfolio of equipment. Here she was one of the top European sales people increasing the installed base in her territory year on year. Furthermore, she was actively involved in installing and training key customers to use this core instrumentation and Leica’s consumables.
Nicky Carless started her career as a histology technician working in both the private sector and the Worcester Royal Infirmary. She then became a research medical technical officer at the Islet Research Laboratory in Worcester – an organisation focused on developing islet transplantation as treatment for diabetes mellitus. Here her main duties were to provide histological processing and its analysis for the laboratory, as well as publishing a variety of academic papers. She then spent six years at Malvern College as senior chemistry technician before moving to Leica.
Commenting on her appointment, Nicky Carless says, “I’ve always had an interest in managed services as they relate to laboratory medicine. I see this as the best way forward for the NHS to procure what they need. Genmed has an excellent reputation in this field which is why I joined the company.”
Robin Modak, Genmed’s chief executive officer, says, “The delivery of vendor neutral managed services can be a complex process where the combination of sales and laboratory expertise is hugely beneficial to then deliver bespoke services for our customers which are clinically relevant. Nicky Carless has a track record of success in both, crucial as we grow our NHS business in the UK.”
-ENDS-
About Genmed
Founded in 2007 and based in London and Wales, Genmed is a vendor neutral managed service provider specialising in the health sector. It works with 40 NHS Trusts and Health Boards around the country where, to date, it has 220 contracts supporting a variety of clinical disciplines such as pathology, surgery, endoscopy, imaging along with medical records, IT and facilities. Genmed’s asset finance requirements are funded by large blue chip partners including Société Generale and GE Capital. Currently Genmed’s contract portfolio totals around £510 million.
Genmed is headquartered in Weybridge, Surrey. For further information, please visit www.genmed.eu
For further information, please contact
Tom Herbst
Tom Herbst PR
T:07768 145571
Email: tom@tomherbstpr.co.uk
Source: RealWire
MEMPHIS, Tenn., July 5, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare announced its four Memphis-based adult hospitals…
TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June…
mCare Digital unveils the mCareWatch MW-241 powered by KORE connectivity ATLANTA, July 5, 2024 /PRNewswire/…
Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of…
Image acquisition and defocusing correction techniques enable observations of atomic-scale magnetic fields at never-before-seen resolution…
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…